BeiGene Ltd. (BGNE)
BGNE Stock Price Chart
Key Info
| Market Cap | 20.90B |
| Revenue (ttm) | 265.67M |
| Net Income (ttm) | -1.51B |
| Shares Out | 1.15B |
| EPS (ttm) | -19.92 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | December 4 |
| Last Price | $222.88 |
| Previous Close | $221.31 |
| Change ($) | 1.57 |
| Change (%) | 0.71% |
| Day's Open | 222.57 |
| Day's Range | 220.64 - 228.64 |
| Day's Volume | 639,450 |
| 52-Week Range | 121.84 - 316.61 |
BGNE Stock News
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #beigene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing in...
BeiGene is planning an IPO on the Shanghai Star Exchange that could raise up to $2.5 billion. BeiGene announced China approval to market Xgeva (denosumab) to prevent skeletal-related events (S...
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces the second approval of XGEVA® (denosumab) in China.
Pharmaceuticals is the only sector that has all three characteristics foreign investors are looking for in Chinese investments: an industry that will consolidate, pro-growth policy reform and ...
CAMBRIDGE, Mass. & BEIJING, China--(BUSINESS WIRE)---- $BGNE #BGNE--Global Phase 3 trial of tislelizumab in second- or third-line non-small cell lung cancer met the primary endpoint at interim...
Innoforce, a Hangzhou company, formed a JV with Thermo Fisher Scientific to build a large biologics and steriles drug development and manufacturing facility in the Hangzhou Airport Economic De...
HEMEL HEMPSTEAD, England & BEIJING, China, & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EUSA Pharma (UK) Limited and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that the Biologics Licens...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene reports recent business highlights, anticipated upcoming milestones and financial results for the third quarter and first n...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #ASH--BeiGene announces data on BRUKINSA® (zanubrutinib) and tislelizumab to be presented at the 62nd ASH Annual Meeting.
SAN DIEGO & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene will hold an exclusive license to the global clinical development and commercialization of BioAtla's investigat...
BeiGene, Ltd. (BGNE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
Here we discuss four biotech stocks, which hold solid potential even amid the coronavirus crisis that continues unabated.
As of late, it has definitely been a great time to be an investor in BeiGene.
Want to invest in an industry that consistently outperforms the S&P 500? Here are three stocks to consider.
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene presents Phase 3 data of tislelizumab in non-squamous non-small cell lung cancer and Phase 2 data of pamiparib in ovarian c...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #beigene--BeiGene announced that the Company will present at the Morgan Stanley 18th Annual Global Healthcare Conference on Thurs, Sept 17...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--Health Canada accepted BeiGene's New Drug Submission for BRUKINSA® (zanubrutinib) in Waldenström’s macroglobulinemia (WM) and grant...
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces inclusion in Shanghai-Hong Kong Stock Connect and inclusion in Hang Seng Composite Index (HSCI).
BeiGene COVID-19 Deal And Other News: The Good, Bad And Ugly Of Biopharma
BEIJING, China & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene and Singlomics enter an exclusive license agreement for Singlomics’ investigational anti-COVID-19 antibodies, includ...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene appoints Corsee Sanders, Ph.D.
GUANGZHOU & BEIJING & CAMBRIDGE, Mass--(BUSINESS WIRE)---- $BGNE--Bio-Thera Solutions and BeiGene announce license, distribution, and supply agreement for Avastin® (bevacizumab) biosimilar BAT...
BeiGene, Ltd. (BGNE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
CAMBRIDGE, Mass. and BEIJING, China, Aug. 06, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercia...
CAMBRIDGE, Mass. and BEIJING, China, Aug. 05, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercia...
BEIJING, China and CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company, today announced that the Center fo...
More than 100% stock gain without posting an operating profit - that’s what Autodesk, Alnylam Pharma, BeiGene, Chegg, and Coupa Software have done over the past three years! This counter-intui...
BEIJING, China and CAMBRIDGE, Mass., July 17, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercia...
CAMBRIDGE, Mass. and BEIJING, China, July 15, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercia...
BeiGene (BGNE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
BeiGene (NASDAQ: BGNE) shares are trading higher on Monday after Amgen announced a $421 million investment in the company.
CAMBRIDGE, Mass. and BEIJING, China, July 12, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercia...
BEIJING, China and CAMBRIDGE, Mass., July 01, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercia...
CAMBRIDGE, Mass. and BEIJING, China, July 01, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercia...
BEIJING, China and CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercia...
BEIJING, China and CAMBRIDGE, Mass., June 19, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercia...
CAMBRIDGE, Mass. and BEIJING, China, June 18, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercia...
CAMBRIDGE, Mass. and BEIJING, China, June 12, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercia...
First approvals for BRUKINSA in China and its first indication for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma First approvals for BRUKINSA in China and its fir...
- Additional follow-up in Phase 3 ASPEN trial continued to show clinically meaningful safety and tolerability advantages for zanubrutinib compared to ibrutinib and demonstrated favorable CR/VG...
– Collaboration to explore multiple solid tumor cancer indications –
CAMBRIDGE, Mass. and BEIJING, China and PETACH TIKVA, Israel, May 21, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on ...
BEIJING, China and CAMBRIDGE, Mass., April 20, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commerci...
BEIJING, China, and CAMBRIDGE, Mass., April 13, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commerc...
Second approval of tislelizumab in China, first in solid tumor Second approval of tislelizumab in China, first in solid tumor
BeiGene CEO on Coronavirus Impact, China Biopharma, Product Pipeline
John Oyler, chairman and chief executive officer at BeiGene Ltd., discusses how coronavirus has impacted the business and his outlook for China’s Biopharma sector. He speaks on “Bloomberg Mark...
- NMPA has suspended the importation, sales and use of ABRAXANE in China supplied by Celgene Corporation, a Bristol Myers Squibb (BMS) company
-- Phase 1 Study Initiated in Australia with IND Cleared to Expand Study to the U.S.-- -- Industry-Leading Scientific Advisory Board Formed to Support Advancement of BGB-3245 --
BeiGene and Vertex Pharmaceuticals aren't nearly as expensive as you may think.
About BGNE
BeiGene,, a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology cancer therapeutics in the People's Republic of China, the United States, and internationally. Its commercial products include BRUKINSA to treat R/R mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumo... [Read more...]
| Industry Biotechnology | IPO Date Feb 3, 2016 |
| CEO John Oyler | Employees 4,600 |
| Stock Exchange NASDAQ | Ticker Symbol BGNE |
Financial Performance
In 2019, BeiGene's revenue was $428.21 million, an increase of 116.03% compared to the previous year's $198.22 million. Losses were -$948.63 million, 40.8% more than in 2018.
Analyst Forecasts
The average 12-month stock price forecast for BeiGene is 293.38, which is an increase of 31.63% from the latest price.